Microfluidic Assembly of Liposomes with Tunable Size and Coloading Capabilities


Authors: JR Hoffman, E Tasciotti, R Molinaro

Journal: Multiple Myeloma

DOI: 10.1007/978-1-4939-7865-6_15

Publication - Abstract

May 25, 2018

Small Molecule Drugs Nucleic Acid Lipid Nanoparticles Oncology
Liposomes used for the delivery of pharmaceuticals have difficulties scaling up and reaching clinical translation as they suffer from batch-to-batch variability. Here, we describe a microfluidic approach for creating reproducible, homogenous nanoparticles with tunable characteristics. These nanoparticles of sizes ranging from 30 to 500 nm are rapidly self-assembled by controlling the flow rates of ethanol and aqueous streams. This method of microfluidic assembly allows for the efficient encapsulation of both hydrophobic and hydrophilic drugs in the lipid bilayer and particle core, respectively, either separately or in combination.

limit search to this category
Advanced Search

Advanced Search

close
  • Publications
  • Application Notes
  • Posters
  • Workshops
  • Videos & Webinars
  • Articles
Search

Browse by Category

  • Application
    • Diagnostic and Imaging
    • Genetic Medicine
    • Hematology
    • Metabolic Disorders
    • Neuroscience
    • Oncology
    • Skeletal Disorders
    • Targeted Drug Delivery
    • Vaccines
    • Other Applications
    • Cell therapy
  • Formulation
    • Liposomes
    • Nucleic Acid Lipid Nanoparticles
    • Polymeric Nanoparticles
    • Other Formulations
  • Payload
    • DNA
    • microRNA
    • mRNA
    • siRNA
    • Small Molecule Drugs
    • Other Payloads


related content

Publication - Abstract

Jul 24, 2018
RNA Biology

Arginase I mRNA Therapy – A Novel Approach to Rescue Arginase 1 Enzyme Deficiency

K.H. Asrani, L. Cheng, C.J. Cheng and R.R. Subramanian

mRNA Nucleic Acid Lipid Nanoparticles Metabolic Disorders
Arginase I (ARG1) deficiency is an autosomal recessive urea cycle disorder, caused by deficiency of the enzyme Arginase I, resulting in accumulation of arginine in blood. Current Standard of Care (SOC) for ARG1 deficiency in patients or those having detrimental mutations of ARG1 ...
Read More


Publication - Abstract

May 25, 2018
Multiple Myeloma

Microfluidic Production and Application of Lipid Nanoparticles for Nucleic Acid Transfection

A. Thomas, S.M. Garg, R.A.G. De Souza, E. Ouellet, G. Tharmarajah, D. Reichert, M. Ordobadi, S. Ip and E.C. Ramsay

siRNA microRNA DNA
Lipid nanoparticles (LNPs) are established in the biopharmaceutical industry for efficient encapsulation and cytosolic delivery of nucleic acids for potential therapeutics, with several formulations in clinical trials.
Read More


Sign Up and Stay Informed
Sign up today to automatically receive new Precision NanoSystems application notes, conference posters, relevant science publications, and webinar invites.
Sign Up